Study Name: ACTIV-6: COVID-19 Study of Repurposed Medications

Study Acronym: ACTIV-6

Study PI(s):

• Susanna Naggie, MD,Duke Clinical Research Institute
• Adrian Hernandez, MD,Duke Clinical Research Institute

Purpose: The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to see them in person.

GPC Partners: 

1. University of Iowa (UIOWA)
2. University of Texas Houston (UTH)
3. Kansas University Medical Center (KUMC)
4. University of Nebraska Medical Center (UNMC)
5. University of Missouri (UMO)
6. Univeristy of Texas Health Sciences San Antonio (UTHSCSA)